Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.29 Average Price Target from Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned a consensus recommendation of “Buy” from the nine analysts that are covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $22.29.

Several equities research analysts have recently weighed in on ZVRA shares. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Canaccord Genuity Group raised their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Thursday, March 13th.

Insider Buying and Selling at Zevra Therapeutics

In other news, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This represents a 17.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares in the company, valued at $231,759.96. This represents a 26.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock valued at $674,176 in the last quarter. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after purchasing an additional 129,600 shares during the period. Barclays PLC raised its holdings in Zevra Therapeutics by 292.6% in the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after acquiring an additional 42,926 shares during the period. FMR LLC boosted its holdings in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after acquiring an additional 2,312,384 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Zevra Therapeutics by 10.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company’s stock valued at $842,000 after purchasing an additional 11,038 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Zevra Therapeutics in the third quarter worth about $94,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $6.56 on Friday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The business’s 50-day moving average price is $7.69 and its 200 day moving average price is $8.14. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The firm has a market cap of $355.00 million, a P/E ratio of -3.33 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. As a group, sell-side analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.